Skip to main content
OpenTrials
Completed

NCT Number: NCT02018627

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

About this study

This study will test the hypothesis that micro-doses of a new formulation of stable glucagon, Xerisol Glucagon (Xeris Pharmaceuticals), will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of a freshly reconstituted formulation of glucagon that has poor stability in solution, Glucagon for Injection (Eli Lilly).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 21 to 80 years old with type 1 diabetes for at least one year.
  • Diabetes managed using an insulin infusion pump using rapid-acting insulin such as insulin aspart (NovoLog), insulin lispro (Humalog), and insulin glulisine (Apidra) for at least one week prior to enrollment.

Exclusion criteria

  • Unable to provide informed consent.
  • Unable to comply with study procedures.
  • Current participation in another diabetes-related clinical trial that, in the judgment of the principle investigator, will compromise the results of the clamp study or the safety of the subject.
  • Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception.
  • End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).
  • Hemoglobin < 11.5 gm/dl.
  • History of pheochromocytoma. Fractionated metanephrines will be tested in patients with history increasing the risk for a catecholamine secreting tumor (paroxysms of tachycardia, pallor, or headache; personal or family history of MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease; episodic or treatment of refractory hypertension, defined as requiring 4 or more medications to achieve normotension).
  • History of adverse reaction to glucagon (including allergy) besides nausea, vomiting, or headache.
  • Inadequate venous access as determined by study nurse or physician at time of screening.
  • Liver failure or cirrhosis.
  • Any other factors that, in the judgment of the principal investigator, would interfere with the safe completion of the study procedures.

Treatment and study plan

Xeris glucagon

Drug

The subject is given an injection of xeris glucagon

Lilly glucagon

Drug

The subject is given an injection of lilly glucagon

Primary outcomes

  1. Tmax

    Time frame: every 2 minutes for 1 hour post-dose of each glucagon

    tmax for Xeris vs. Lilly (non-inferiority)

Secondary outcomes

  1. AOCGIR

    Time frame: every 2 minutes for 1 hour post-dose of each glucagon

    Area over the curve for glucose infusion rate in the hour following administration (AOCGIR) for Xeris vs. Lilly (non-inferiority)

  2. GIRmin

    Time frame: every 2 minutes for 1 hour post-dose of each glucagon

    Minimal glucose infusion rate (GIRmin) for Xeris vs. Lilly (non-inferiority)

  3. t½Max

    Time frame: every 2 minutes for 1 hour post-dose of each glucagon

    Glucagon t½max for Xeris vs. Lilly (non-inferiority)

  4. Injection Pain

    Time frame: immediately after injection

    Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:

    -average Injection pain on a 10 cm standard VAS: 0 = no pain, 10 = worst imaginable pain reported immediately after injection of glucagon

  5. Injection Site Erythema

    Time frame: within 1 hour of injection

    Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:

    -Injection site erythema or other local reaction, maximum diameter within 1 hour of injection

  6. Maximal Nausea

    Time frame: within 1 hour of injection

    Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:

    -Maximal nausea within 1 hour of injection on a 10 cm VAS: no nausea = 0, vomiting = 10

  7. Dermal Response (Draize Scale for Erythema and Eschar Formation)

    Time frame: within 1 hour of injection

    Average grade on the erythema and eschar formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)

  8. Dermal Response (Draize Scale Grade for Edema Formation)

    Time frame: within 1 hour of injection

    Average grade on the edema formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)

Sponsors and collaborators

Lead sponsor

Steven J. Russell, MD, PhD

Other

Registry information

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Dec 23, 2013
Registry last updated
Oct 8, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.